CAPECITABINE INDUCED CARDIOTOXICITY IN A HIGH-RISK PATIENT
DOI:
https://doi.org/10.30890/2567-5273.2025-39-04-065Keywords:
cardiotoxicity, 5-fluorouracil, capecitabine, heart failure, arrhythmia, speckle echocardiography, strain.Abstract
The cardiotoxicity of chemotherapy has long been known. There are many studies on the manifestations of cardiotoxicity during treatment with many groups of chemotherapy drugs, and specifically treatment with drugs of the 5-fluorouracil group. CardiotoxicReferences
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., Lopez Fernandez, T., Mohty, D., Piepoli, M. F., Tamargo, J., Torbicki, A., Suter, T. M., & ESC Scientific Document Group (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 2016. 37(36), 2768–2801 DOI: 10.1093/eurheartj/ehw211
Allison, J. D., Tanavin, T., Yang, Y., Birnbaum, G., & Khalid, U. (2020). Various Manifestations of 5-Fluorouracil Cardiotoxicity: A Multicenter Case Series and Review of Literature. Cardiovascular toxicology, 20(4), 437–442. DOI: 10.1007/s12012-020-09562-w
Jurczyk, M., Król, M., Midro, A., Kurnik-Łucka, M., Poniatowski, A., & Gil, K. (2021). Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J. Clin. Med. 2021 Sep 27;10(19):4426. DOI: 10.3390/jcm10194426
Koca D, Salman T, Unek I, et al. Clinical and electrocardiographychanges in patients treated with capecitabine. Chemotherapy.2011;57 (5):381–387. DOI: 10.1159/000331645
Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. JCO.1989;7(4):509–514
Jurczyk, M., Król, M., Midro, A., Kurnik-Łucka, M., Poniatowski, A., & Gil, K. (2021). Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. Journal of clinical medicine, 10(19), 4426. DOI: 10.3390/jcm10194426
Dyhl-Polk, A., Vaage-Nilsen, M., Schou, M., Vistisen, K. K., Lund, C. M., Kümler, T., Appel, J. M., & Nielsen, D. L. (2020). Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer. Acta oncologica (Stockholm, Sweden), 59(4), 475–483. DOI:10.1080/0284186X.2019.1711164
Koca, D., Salman, T., Unek, I. T., Oztop, I., Ellidokuz, H., Eren, M., & Yilmaz, U. (2011). Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy, 57(5), 381–387. DOI:10.1159/000331645
Dent, S. F., Morse, A., Burnette, S., Guha, A., & Moore, H. (2021). Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current oncology reports, 23(11), 128. DOI:10.1007/s11912-021-01114-x
Curigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A.R., Lancellotti P., et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 2020;31:171–190. DOI: 10.1016/j.annonc.2019.10.023
Jin X., Bai Y., Gao L., Wu S. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. Cancer Chemother. Pharmacol. 2019;84:599–607. DOI: 10.1007/s00280-019-03888-1
Polk A., Shahmarvand N., Vistisen K., Vaage-Nilsen M., Ole Larsen F., Schou M., Lisbeth Nielsen D. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: A retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open. 2016;6:e012798. DOI: 10.1136/bmjopen-2016-012798.
Jensen S.A., Sørensen J.B. Risk Factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother. Pharmacol. 2006;58:487–493. DOI: 10.1007/s00280-005-0178-1.
Jensen SA, Hasbak P, Mortensen J, et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28: 5280–5286. DOI: 10.1200/JCO.2009.27.3953
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., DeCara, J. M., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European heart journal. Cardiovascular Imaging, 15(10), 1063–1093. DOI:10.1093/ehjci/jeu192
Bountioukos, J.K. Doorduijn, J.R.T.C. Roelandt, E.C. Vourvouri, J.J. Bax, A.F.L. Schinkel, M.D. Kertai, P. Sonneveld, D. Poldermans, Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity, European Journal of Echocardiography, Volume 4, Issue 4, December 2003, Pages 300–305, DOI:10.1016/S1525-2167(03)00017-9
Clément Charbonnel, Raphaele Convers-Domart, Sophie Rigaudeau, Anne Laure Taksin, Nicolas Baron, Juliette Lambert, Stéphanie Ghez, Jean-Louis Georges, Hassan Farhat, Jérôme Lambert, Philippe Rousselot, Bernard Livarek, Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity, European Heart Journal - Cardiovascular Imaging, Volume 18, Issue 4, April 2017, Pages 392–401, DOI:10.1093/ehjci/jew223
Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., Lancellotti, P., Muraru, D., Picard, M. H., Rietzschel, E. R., Rudski, L., Spencer, K. T., Tsang, W., & Voigt, J. U. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European heart journal. Cardiovascular Imaging, 16(3), 233–270. DOI:10.1093/ehjci/jev014
Dyhl-Polk A., Schou M., Vistisen K.K., et al. Myocardial ischemia induced by 5-fluorouracil: a prospective electrocardiographic and cardiac biomarker study. Oncologist. 2021;26:e403–e413. DOI: 10.1002/onco.13536.
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., … ESC Scientific Document Group (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, 43(41), 4229–4361. DOI:10.1093/eurheartj/ehac244
Anaka, M., & Abdel-Rahman, O. (2022). Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment. Cancer management and research, 14, 273–285. DOI:10.2147/CMAR.S273544
Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J. J. M., Frödin, J. E., Shah, C. H., Sorbye, H., Ristamäki, R., Halonen, P., Soveri, L. M., Heervä, E., Ålgars, A., Bärlund, M., Hagman, H., McDermott, R., O'Reilly, M., Röckert, R., Liposits, G., Kallio, R., … Glimelius, B. (2022). Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO open, 7(3), 100427. DOI:10.1016/j.esmoop.2022.100427
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
